Certara connects life-science AI with modeling and regulatory workflows

Certara combines scientific software and specialist services across drug discovery and development. Its AI offer sits alongside established informatics, biosimulation and regulatory tools. The important distinction is between generating or organizing information and establishing the scientific evidence behind it. Certara can support several stages of a program, but buyers should define the particular workflow, product entitlement and review responsibility they need.

01 / ProductA portfolio spanning discovery data and submission work

Certara.AI is presented as a platform for working across life-science data sources with specialized AI applications and flexible model selection. The company describes both cloud and internal-infrastructure deployment options. These are enterprise capabilities to scope with the vendor, rather than a promise that every application is included in one public chat subscription.

CoAuthor brings generative drafting, structured reusable content and regulatory templates into Microsoft Word. D360 focuses on access, visualization and analysis of research information, including molecular structures, sequences and assay data. The products address different handoffs: one helps scientists interpret discovery data; the other helps writers turn controlled source information into documents.

Simcyp is a physiologically based pharmacokinetic modeling suite. It uses a mechanistic approach to simulate drug behavior in biological populations. Calling every part of Certara “generative AI” would obscure that distinction. The broader company story describes scientific and regulatory services alongside software, which helps explain why a deployment may involve both licensed tools and expert work.

02 / AudienceMatch the product to the team’s actual handoff

A regulatory writing group may need to produce consistent study documents from controlled tables and approved text. A discovery team may instead need to combine assay information across systems before selecting compounds. Both could be Certara customers, but they should not start with the same pilot or assume the same evidence establishes value for their use case.

CoAuthor is relevant where Word-based drafting, repeated study information and source-grounded summaries create substantial coordination work. The evaluation should include the writers and reviewers who resolve scientific meaning. A document that is formatted consistently can still misstate a result, so formatting efficiency and factual fidelity need separate acceptance criteria.

D360 is relevant when researchers need self-service views over scientific data without repeatedly asking IT to prepare extracts. Compare that data-access requirement with the Owkin blueprint, which concerns AI-assisted biomedical research, and the Recursion blueprint, which describes a discovery company’s experimental platform. These comparisons clarify whether the team needs information infrastructure, analytic collaboration or a drug-development partner.

03 / WorkflowA proposed source-to-document evaluation

Consider a proposed CoAuthor pilot for a completed study whose source package is already approved for internal use. Choose a bounded document section and define exactly which tables, listings, figures and reference text the assistant may use. Keep a copy of the approved baseline so the team can distinguish changes in wording from changes in scientific meaning.

Select the appropriate template and reusable content before generating prose. Stable items such as study identifiers and terminology should come from controlled records. Ask the system to draft a limited summary, then have a writer check each consequential statement against the underlying material. Review omitted qualifications as well as invented claims: a fluent sentence can become misleading by losing a condition or exception.

Next, deliberately update one permitted source and inspect the revision process. The reviewer should be able to tell which version of a table supported a statement and whether neighboring sections also need attention. CoAuthor advertises traceability and version control; the pilot should demonstrate how these work in the team’s actual document process rather than treating their presence in a feature list as sufficient evidence.

Measure accepted writing time, source-checking time and the number of substantive corrections. Retain errors as evaluation evidence. A faster first draft may provide little overall benefit if review expands disproportionately. Conversely, reliable reuse of controlled content can matter even where a writer chooses to rewrite most generated prose. This proposed evaluation has not been performed by Sequenced.

04 / Commercial modelCommercial scope follows the selected software and services

The reviewed contact page routes organizations to a sales inquiry, and the CoAuthor, Certara.AI, D360 and Simcyp pages offer demonstrations. These sources did not establish a universal numerical price for the portfolio. Treat the commercial discussion as product-specific, with separate questions about licenses, hosting, integrations, implementation and scientific support.

For CoAuthor, establish the licensed writing environment, repository connections and template customization included in the offer. For D360, define data connectors and any external-partner access. For Simcyp, clarify the modeling capability and support appropriate to the intended team. A demonstration across several products does not prove that all of them are bundled in the same agreement.

It is useful to divide the proposed budget into recurring software, initial configuration and ongoing scientific work. This is a suggested budgeting method, not Certara’s published pricing formula. The key is to make the deliverable explicit: a configured tool, a completed analysis and an expert-reviewed document are different purchases, even when they participate in the same development program.

05 / DistinctionsDomain structure makes the AI offer more specific

Certara’s proposition is strongest where domain information must retain its structure. D360 supports chemical and sequence representations, assay measurements and programmatic data access. A research question can therefore remain connected to molecular identity and experimental context instead of being reduced to a folder of plain-text documents. The practical advantage depends on the quality and accessibility of the connected records.

CoAuthor’s structured content and Word integration address a different problem: repeated regulated-document material needs consistent wording, metadata and review. Its product page describes source-restricted generation and collaboration. Those features can help organize a controlled writing process, but users still need to determine whether an output accurately reflects the permitted source.

Simcyp gives the portfolio a substantial modeling component beyond document AI. Its biological simulations should be evaluated through model assumptions, inputs and relevant validation. Generative tools might help researchers organize or communicate such work, yet a generated explanation is not a substitute for reviewing the underlying mechanistic model. Keeping that boundary visible makes the portfolio easier to assess without dismissing either approach.

06 / LimitationsSeparate vendor capabilities from program-level assurance

The product pages contain claims about efficiency, security and scientific impact. This article establishes the advertised functions and commercial routes, not an independent reproduction of performance claims. A buyer should request the methodology and relevant conditions behind any outcome figure used in its business case, especially when comparing first-draft speed with a fully reviewed deliverable.

For Certara.AI, investigate which models and data sources are actually enabled in the proposed deployment. “Model agnostic” does not mean every model is interchangeable for every task, or that an organization can ignore inference location and access permissions. Test a query against a permitted record and a similarly named restricted record to see how the implementation handles the boundary.

For scientific modeling, define the intended decision and the degree of evidence needed before interpreting a prediction. A pharmacokinetic simulation may support one development question without answering another. For writing, retain human responsibility for source selection, interpretation and final approval. Certara’s portfolio can connect these activities, but the organization still owns how evidence becomes a decision.

07 / DecisionBuy the handoff you can actually evaluate

Start with the most expensive or error-prone transition in the current process: finding discovery data, interpreting a model, or drafting a controlled document. Assign one product and one accountable team to that transition, then expand only after the output can be traced back to its source and reviewed at an acceptable cost. This produces a clearer decision than evaluating the entire Certara portfolio as a single AI feature.